Marijuana rescheduling is often treated as a technical matter for the DEA to sort out. It isn’t. The scheduling system exists only because Congress built it—and a decision this consequential, one that would hand the marijuana industry a federal tax windfall and a veneer of legitimacy, should not be made by agency officials acting alone. Both Congress and the President hold real tools to ensure it isn’t.
Congress Wrote the Rules—and Can Enforce Them
Congress created the modern scheduling framework when it passed the Controlled Substances Act (CSA). That authorship matters: the people’s elected representatives, not unelected bureaucrats, are supposed to make momentous changes to federal drug law. Congress has at least four ways to assert that role.
Legislation
Congress can amend the CSA directly, and it can also rein in an executive branch that gets ahead of the science. In 2023, Senator Cynthia Lummis (R-WY) and Senator Steve Daines (R-MT) introduced the Deferring Executive Authority (DEA) Act, which would require congressional review before any rescheduling rule could take effect. As Lummis put it, “Congress makes the laws in this country, not D.C. bureaucrats.”
Oversight
Committees can hold hearings and demand answers when an administration appears to be rushing a politically driven decision without compelling scientific evidence.
Appointments
The officials steering rescheduling at DOJ, DEA, and HHS generally require Senate confirmation—giving senators leverage to scrutinize policy before a nominee is ever seated.
Funding
The power of the purse is the clearest check of all. In May 2026, the House Appropriations Committee approved a spending bill barring federal funds from being used to reschedule marijuana—even as the executive branch pushed ahead. The 32-28 vote shows that meaningful congressional resistance is alive, and that an agency rule can be frozen no matter how eager the bureaucracy is to act.
The President Set This in Motion
The administrative process now underway is a product of presidential direction, not independent scientific consensus. President Biden’s October 2022 request launched the review, and after President Trump’s executive order to expedite it, Acting Attorney General Todd Blanche moved state-licensed medical marijuana products to Schedule III. That a single appointee can shift federal policy this far underscores the problem—and the need for congressional input.
The Bottom Line
Rescheduling is being driven from the top down. Congress has every constitutional tool to demand it be done the right way: deliberately, transparently, and grounded in public health rather than industry pressure.